MP129 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
MP129 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed MP129 in detail.
, Support Vector Machine Identification of Small Molecule Binders to an Understudied Allosteric Site of SARS‐CoV‐2 Mpro for Next‐Generation PROTAC‐Based Therapeutics, Archiv der Pharmazie, doi:10.1002/ardp.70169
ABSTRACT The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has underscored the urgent need for novel antiviral strategies. One of the primary targets of interest is the SARS‐CoV‐2 main protease (Mpro), which plays a crucial role in viral replication. Building on our prior work involving machine learning (ML)‐based virtual screening for potential Mpro inhibitors, we sought to experimentally validate top‐ranked candidates. Microscale thermophoresis (MST) was used to assess the binding affinity, leading to the identification of three promising hits from a library of 180 compounds. Notably, one compound demonstrated high‐affinity binding to SARS‐CoV‐2 Mpro ( K d = 2.8 ± 0.9 µM). However, enzymatic assays revealed that none of the hit compounds inhibited the activity of the protease, suggesting a non‐competitive binding. Docking and molecular dynamics (MD) simulations allowed to identify an accessory site in which the compounds exhibited stable interactions. These findings suggest that the identified compounds may serve as a starting point for the rational design of degradation‐inducing strategies, such as proteolysis‐targeting chimeras (PROTACs), targeting SARS‐CoV‐2 Mpro, and highlight the value of integrating ML‐driven discovery with biophysical and computational validation in antiviral drug development.